Regenxbio(NASDAQ) RGNX

REGENXBIO helps people by fixing faulty genes inside their cells. These treatments help patients with serious eye, muscle, and brain diseases. A single dose aims to improve health for a long time.

Healing Through Human Genes

• Retinal Disease Treatments: Gene therapies for vision loss including wet age-related macular degeneration and diabetic retinopathy.
• Neuromuscular Medicines: Programs for Duchenne muscular dystrophy, a fatal genetic condition that weakens muscles in children.
• Neurodegenerative Solutions: Treatments for rare brain disorders where patients lack enzymes needed to break down waste in cells.
• NAV Technology Platform: Proprietary system using modified viruses to deliver functional genes to specific parts of the body.
• Licensing and Royalties: Rights granted to other drugmakers to use the company's gene delivery technology for their own medicines.

Genes, Patents, and Partnerships

• Launched a major eye care collaboration with AbbVie in September 2021 to develop and sell vision treatments.
• Partnered with Nippon Shinyaku in March 2025 for rare disease treatments in the United States and Asia.
• Built a specialized manufacturing center in Maryland that began operating at commercial scale in mid-2022.
• Modified the AbbVie agreement in August 2025 to start a new late-stage trial for diabetic retinopathy.

What Makes the Company Stand Out?

The company operates its own in-house factory capable of producing large batches to meet future global demand. Its delivery technology supports two approved treatments and has been used to treat thousands of patients.

Checking the Scoreboard

• Revenue grew to $30.3 million in Q4 2025, a 43% increase from the previous year.
• Gross profit reached $24.4 million in Q4 2025, up 63.9% from Q4 2024.
• Net loss reached $67.1 million in Q4 2025, a loss that deepened 31.2% from the prior year.
• Operating cash flow was -$52.3 million in Q4 2025, which deepened 65.3% from Q4 2024.
• Two major partners, Novartis Gene Therapies and Nippon Shinyaku, accounted for 99% of revenue in 2025.

The Path Forward

REGENXBIO is moving from developing technology to manufacturing and selling its own complex genetic medicines. Its partnerships with large pharmaceutical firms provide the essential resources needed for expensive late-stage clinical trials.